FLOT compared to FOLFOX/XELOX as a neoadjuvant chemotherapy in locally advanced gastric cancer: Experience of two clinics.

• DOI: 10.1200/jco.2024.42.3_suppl.361
• Publication Date: 2024-01-22T21:12:58Z
• Authors: Nikolay Semenov; Kamil Dalgatov; Roman Izrailov; Lyudmila Zhukova
• Keywords: FOLFOX; Regimen; Neoadjuvant Therapy; Chemotherapy regimen

361 Background: The optimal regimen of neoadjuvant chemotherapy (NCT) in locally advanced gastric cancer (GC) remains controversial, especially whether triplet (FLOT) or duplet (FOLFOX/XELOX) is superior since escalation does not always lead to significant clinical improvement. aim this study assess efficacy and regimens as a approach GC via retrospective data. Methods: We queried the data for 334 patients with (cT2-4 cN+) diagnosed 2016–2023 yy administered multi-agent NCT: FLOT XELOX/FOLFOX. primary endpoints were ratio disease progression on NCT, rates ypN0, pathological complete response (pCR). Secondary included free survival (PFS) overall (OS). Results: 156 (out total study) received doublet NCT (FOLFOX/XELOX, 8/6 cycles respectively), 61.5% males, median age was 67.4 (range 21.3-85.4) years, 88.2% had cT3-4. 22.4% gastroesophageal junction (GEJ) adenocarcinoma. 177 treated triple (FLOT, 8 cycles), 62.1% 59.9 89.2% cT3-4, GEJ adenocarcinoma 21.0%. At follow up 34.7 months (mth) using associated better outcomes. who have progressed 21.5% 31% arms, respectively (p=0.098). Rates ypN0 50.5% arm 43.7% XELOX/FOLFOX (p=0.36). pCR achieved 8.2% 6.3% (p=0.59). Median PFS 20.3 mth comparison 15.7 FOLFOX/XELOX (p=0.012). OS reached (NR) 25.1 (p= 0.003). Patients conversed resectable 34.5 23.1 (p=0.024). these subgroups NR 37.0 (p=0.003). Conclusions: report that more favorable option setting cancer. increased shows statistically difference OS.